Cellebrite DI Ltd. $CLBT Shares Sold by Y.D. More Investments Ltd

Y.D. More Investments Ltd lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 60.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 110,151 shares of the company’s stock after selling 171,665 shares during the period. Y.D. More Investments Ltd’s holdings in Cellebrite DI were worth $1,518,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Cooper Creek Partners Management LLC purchased a new stake in Cellebrite DI during the 3rd quarter valued at approximately $55,999,000. Granahan Investment Management LLC grew its stake in shares of Cellebrite DI by 1,108.5% in the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after purchasing an additional 2,411,726 shares during the last quarter. Capital International Investors acquired a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $41,073,000. Invesco Ltd. increased its holdings in shares of Cellebrite DI by 58.6% in the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after purchasing an additional 2,054,644 shares during the period. Finally, Artisan Partners Limited Partnership purchased a new stake in shares of Cellebrite DI during the fourth quarter worth approximately $25,871,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CLBT shares. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. DA Davidson started coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Finally, Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Insider Activity

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the sale, the chief executive officer owned 590,777 shares in the company, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Price Performance

CLBT opened at $15.94 on Monday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The firm has a market capitalization of $3.98 billion, a P/E ratio of 56.93, a P/E/G ratio of 1.97 and a beta of 1.17. The firm’s 50 day moving average is $13.77 and its 200-day moving average is $14.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.